Fabrazyme Biosimilar Marketed in Japan Under New Agreement

Fabrazyme Biosimilar Marketed in Japan Under New Agreement

322817

Fabrazyme Biosimilar Marketed in Japan Under New Agreement

JCR Pharmaceuticals and Sumitomo Dainippon Pharma have teamed up to market and commercialize in Japan agalsidase beta BS, a biosimilar of Fabrazyme, an already approved treatment designed to replace a critical enzyme missing in people with Fabry disease. According to a company press release, “This marketing alliance between the two companies will further enhance both partner’s contribution to the treatment of Fabry disease patients.” In Fabry disease, the alpha-galactosidase A (Gal A) enzyme is missing…

You must be logged in to read/download the full post.